29 October 2020 - Newsletter

SHS invests in Salvia, a Dutch-based specialist in neurostimulation

Migraine is one of the main causes of physical limitations. One in seven persons has experienced a migraine at some point in the past. Chronic migraine affects 5 percent of all migraine patients. With neurostimulation, Dutch-based Salvia BioElectronics B.V. is developing a promising therapeutic approach that offers many sufferers a reason to hope. SHS is investing in this innovative firm as part of a financing round (total volume: 26 million euros) and is pleased to be able to contribute towards the development of migraine therapy. Read more about our latest shareholding here: https://t1p.de/0xb9